Murray, Nigel P.Guzman, EghonDel Prado, Monica2021-12-172021-12-172021-11Hematology, Transfusion and Cell Therapy, Vol. 43, N°4, (2021) p. 515-5172531-1379http://hdl.handle.net/20.500.12254/2155The case report demonstrates the importance of investigating alternative causes of a prolonged APTT in patients with Covid-19. Although Covid-19 is associated with thrombotic complications it is possible that immune dys-regulation associated with SARS-CoV-2 may lead to other coagulation factor inhibitors and a hemorrhagic tendency. Clinical decisions on anticoagulant treatment may be influenced by the APTT and modified in patients with Covid-19. Management of these cases requires the clinical acumen to balance the potential for haemorrhagic and thrombotic complications of SARS-CoV-2 infection. The abnormalidades in the coagulation tests may persist long after clinical remission and resolution of inflammatory markers.enAtribución-NoComercial-CompartirIgual 3.0 Chile (CC BY-NC-SA 3.0 CL)COVID-19Factor XII deficidencyArtículohttp://orcid.org/0000-0001-8154-8550https://doi.org/10.1016/j.htct.2021.06.0172531-1387